# Observational Study to Assess Endpoint Operational Feasibility & Measurement Properties in Patients with Retinal Degeneration

> **NCT06375239** · — · RECRUITING · sponsor: **Ray Therapeutics, Inc.** · enrollment: 120 (estimated)

## Conditions studied

- Retinitis Pigmentosa
- Choroideremia
- Stargardt Macular Dystrophy
- Stargardt Disease
- Geographic Atrophy from Age-related Macular Degeneration
- X-lined Retinoschisis
- Retinal Dystrophies

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06375239
- **Lead sponsor:** Ray Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-05
- **Primary completion:** 2026-04-30
- **Final completion:** 2026-04-30
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2025-01-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06375239

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06375239, "Observational Study to Assess Endpoint Operational Feasibility & Measurement Properties in Patients with Retinal Degeneration". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT06375239. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*